The FDA has granted accelerated approval to Johnson & Johnson’s Rybrevant (amivantamab-vmjw) for head and neck cancer that has returned after prior chemotherapy and immunotherapy. The decision marks a notable checkpoint for EGFR/Met-targeted bispecific oncology strategies in recurrent disease settings. For clinicians and developers, the approval underscores continued regulatory openness to targeted therapies in hard-to-treat relapsed populations, particularly where response-rate and durability frameworks support faster pathways. The next practical step will be how subsequent confirmatory evidence may reshape use patterns and combination planning in head and neck cancer cohorts where targeted EGFR-family engagement is biologically relevant.